
EMA discussing executive director post
pharmafile | December 3, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | EMA, Guido Rasi, andreas pott
The European Medicines Agency has confirmed that Andreas Pott will remain in charge of the body in place of the ousted Guido Rasi as executive director, until the European Commission finalises his permanent replacement.
Pott (pictured) is stepping into Rasi’s shoes due to a judgment by the European Union Civil Service Tribunal that annulled his appointment as the agency’s executive director in November.
The European Commission now plans to publish a vacancy announcement for the post shortly, and the EMA board chaired by Sir Kent Woods has said that Pott will be in charge for the interim period.
The EMA says Sir Woods has been asked to explore how Guido Rasi can “best support the agency in the coming months as his contract is in operation”.
Rasi found himself at the centre of a legal wrangle after a former rival for the post complained to the European Union Civil Service Tribunal.
The tribunal ruled that the EC had not followed proper procedures during the recruitment of Rasi, who was appointed in October 2011 – and since the EC’s decision has been annulled, the EMA’s decision to appoint Rasi went the same way.
Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera
Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence …

Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis
Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European …






